Objectives: Non-tuberculous mycobacteria (NTM) are emerging pathogens causing difficult-to-treat infections. We tested a new assay (GenoType NTM-DR) that detects natural and acquired resistance mechanisms to macrolides and aminoglycosides in frequently isolated NTM species.
Introduction
Non-tuberculous mycobacteria (NTM) are opportunistic pathogens that cause lung and extra-respiratory infections mainly in the context of underlying disease or iatrogenic procedures. [1] [2] [3] [4] Most NTM infections cannot be cured in the same way that TB can be cured because NTM harbour natural mechanisms of resistance to the main first-line and second-line antimicrobial agents used to treat TB. 5 This resistance profile is species specific and identification of the species should precede treatment choice. 6 Antibiotic susceptibility testing is recommended for NTM in the context of proved infection. 4 The antibiotics that must be tested are those with demonstrated activity on a given species, and they must be tested when acquired resistance is suspected, i.e. recurrent infection or a previously treated patient. The recommended method for NTM antibiotic susceptibility testing is broth microdilution and this is usually performed on a sub-culture. 7 The time to results depends on the time to grow of the mycobacterial species, with results obtained after several days (rapid-growing mycobacteria) or after V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
weeks (slow growers) of incubation, and uncertainty arising due to the degradation of antibiotics during such a long incubation time.
Acquired resistance to antibiotics in NTM is known to be mediated by mutations in genes involved in the mechanism of action, e.g. rrl, encoding the 23SRNA, for macrolides such as clarithromycin and azithromycin, and rrs, encoding the 16SRNA, for aminoglycosides such as amikacin and tobramycin. Mutations of rrl leading to clarithromycin and azithromycin resistance (Escherichia coli numbering system) were described at positions 2058 and 2059 in isolates of Mycobacterium avium complex, Mycobacterium abscessus and Mycobacterium chelonae. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Acquired resistance to aminoglycosides such as amikacin or tobramycin has also been described in these NTM species, the mechanism being a point mutation in the rrs gene, encoding 16S rRNA, such as the nucleotide change a1408g (E. coli numbering). [18] [19] [20] [21] erm genes, encoding 23SRNA methyltransferases, are involved in natural resistance to clarithromycin but have been described only in certain NTM species, such as erm (41) in M. abscessus. In this species, erm(41) gene sequences are characteristic of defined phyletic groups associated with the M. abscessus subspecies (subsp. abscessus, subsp. bolletii and subsp. massiliense), but M. abscessus subsp. abscessus has shown two erm(41) genotypes (nucleotide t28 or c28); the t28 genotype confers clarithromycin resistance, whereas the c28 genotype does not. 14, 22 Whereas an intact erm(41) gene is found in isolates of subsp. abscessus and subsp. bolletii, a non-functional 276 bp-deleted gene is found in subsp. massiliense.
17,23-25
The aim of this study was to evaluate the performance of a new molecular assay for the rapid detection of clarithromycin and aminoglycoside resistance in the main clinically encountered NTM, including M. abscessus (subsp. abscessus, bolletii and massiliense), M. chelonae and those belonging to the M. avium complex (M. avium, Mycobacterium intracellulare and Mycobacterium chimaera). The performance was measured on clinical isolates and reference strains, characterized for erm (41) , rrl and rrs sequences and studied for macrolide and aminoglycoside phenotypic antibiotic susceptibility testing. Overall, the results of the new molecular assay are concordant with reference methods and demonstrate that the assay can be used as the first molecular test for antimicrobial resistance in NTM.
Materials and methods

NTM clinical isolates
Overall, 108 bacterial isolates were tested with the GenoType NTM-DR test, including 9 reference strains and 99 clinical isolates from the French National Reference Center for Mycobacteria and Lariboisière Hospital Bacteriology Laboratory. M. abscessus ATCC 19977 and 22 other isolates were tested three times each to assess repeatability. All isolates were tested in two laboratories for assessing reproducibility and the test was repeated in the case of discordance. 17, 26 Six bacterial strains of species not included in the assay were tested for specificity: M. tuberculosis strain H37Rv and clinical isolates of Mycobacterium scrofulaceum (n " 1), Mycobacterium xenopi (n " 1), Mycobacterium fortuitum (n " 1), Actinomyces ondotolyticus (n " 1) and Nocardia farcinica (n " 1). The last two species were chosen as non-mycobacterial isolates with a high gc% content. A total of 94 clinical isolates and 8 reference strains belonging to the five mycobacterial species targeted by GenoType NTM-DR were tested. Clinical isolates were retrieved from respiratory specimens for 70 of them [among which 28/70 (40%) were from cystic fibrosis patients] and 24 from various sites (skin and soft tissue for 10, osteo-articular for 3, adenopathy for 4, blood for 2, urines for 1 and others for the remaining 4).
DNA extraction and PCR sequencing
Total DNA was extracted using GenoLyse v (2.0) (Hain Lifescience, Nehren, Germany). Mycobacterial isolates were identified by GenoType Mycobacterium CM (Hain Lifescience) and PCR sequencing of hsp65, rpoB or other genes when needed. 27 The erm(41) gene and its promoter region, and the regions of rrl and rrs genes involved in resistance, were amplified by PCR as previously described. 15, 22 GenoType NTM-DR testing
The NTM-DR kit (Hain Lifescience) includes an amplification mix system (AM-A and AM-B) and strips coated with different specific oligonucleotides (DNA probes) using DNA STRIP V R technology. The probes were designed to hybridize with the sequences of the WT alleles (WT probes) or alleles containing a specific mutation (MUT probes) ( C. The denaturation solution was mixed with 20 lL of the amplified sample and submitted to the usual protocol for hybridization.
To assess positive and negative bands, the DNA strips were glued to an evaluation sheet after hybridization and a template (shown in Figure 1 ) was aligned parallel to the conjugate control band of the respective strip. To validate the test results, control bands should be positive for conjugate and amplification controls. Quality controls included a negative (ultrapure water) control and a positive [M. abscessus subsp. abscessus erm(41) T28 ATCC 19977] control; the controls were used for each set of 12 tests.
The limit of detection for DNA was measured by testing various dilutions of bacterial and DNA suspensions. The specificity of the probes was determined by testing six DNAs from bacterial species other than those detected by the DNA strip (four NTM and two other bacteria, detailed above).
Antibiotic susceptibility testing
MICs of clarithromycin and amikacin were obtained by the reference microdilution method using Sensititre RAPMYCO or SLOMYCO microplates (Trek Diagnosis Systems). 7 Susceptibility and resistance were assessed according to CLSI recommendations.
7,21
Results
Results of GenoType NTM-DR testing for molecular detection of resistance in M. avium complex
The results are presented for each species in Table 2 and representative patterns are shown in Figure 2 . For 34 isolates (31 clinical isolates and 3 reference strains) belonging to the M. avium complex, the speciation results yielded by the test were concordant with the reference DNA sequencing for 16 M. avium isolates, 10 M. intracellulare and 8 M. chimaera. For 27 isolates with a WT rrl allele and without acquired resistance to macrolides and aminoglycosides, only an rrl WT band was observed. The GenoType NTM-DR test detected the seven isolates with rrl mutations known to confer Mougari et al. macrolide resistance, as evidenced by positive hybridization with the MUT1, MUT2 or MUT3 bands (Table 3) . No isolate was observed to display the a2059g (MUT4) allele, but the sample size was small (seven isolates with mutations). For one M. avium isolate (Ma92239) harbouring a heretofore undescribed rrl mutation (a2057c), hybridization was unexpectedly observed with the MUT2 probe. In three isolates (two M. avium isolates and one M. chimaera isolate), more than one rrl band was observed due to a double population (heterogeneous pattern shown in Figure 2 ): (i) a mixture of the WT bands and one MUT band was observed for one isolate (Ma1); and (ii) two MUT bands were observed for the two others isolates (Ma14 and Mi5). The heterogeneous pattern was also observed using the reference Sanger sequencing as a 'double peak', except for the M. chimaera isolate (Mi5), for which only the mutation a2058c, corresponding to MUT1, was found. For two isolates harbouring the a2058t rrl mutation, because this mutation is not present as a specific MUT band, the corresponding patterns showed the absence of the WT band only.
For the molecular detection of aminoglycoside resistance, 32 isolates with a WT rrs allele showed a WT band and 2 isolates (1 M. avium and 1 M. intracellulare) with an a1408g rrs mutation were accurately detected by the absence of WT and the presence of rrs MUT1 (Table 3 ).
In conclusion, for the M. avium complex, the results of the GenoType NTM-DR test were concordant with the genotypic pattern (WT or mutation) for 34/34 (100%) isolates. The mutations were specified at the nucleotide position level in rrl (a2058 or a2059) for 7/8 isolates harbouring mutations and in rrs (a1408) for 2/2 isolates. One exception was the isolate harbouring the new mutation a2057c, for which hybridization was observed with the MUT2 probe, designed for the specific a2058g mutation. Overall, the exact nucleotide changes, e.g. a2058c for MUT1, were specifically detected in 4/8 isolates with mutations.
The predictions of the GenoType NTM-DR test for susceptibility and resistance to clarithromycin and amikacin were concordant with the phenotypic antibiotic susceptibility testing results for 32/34 (94.1%) isolates (Table 4) . Genotypic and phenotypic results were discordant for two M. avium isolates, both with a WT rrl allele detected by GenoType NTM-DR and PCR sequencing, but exhibiting a clarithromycin MIC of 32 and .64 mg/L, respectively. For the M. avium isolate harbouring the mutation a2057c, the clarithromycin MIC was 64 mg/L. We observed that one isolate was MDR, i.e. resistant to clarithromycin and amikacin, and harboured mutations in rrl (a2059c) and rrs (a1408g).
Results of GenoType NTM-DR testing for molecular detection of resistance in M. abscessus
For 53 strains (49 clinical isolates and 4 reference strains) belonging to M. abscessus, the test results were concordant for the speciation and the erm(41) sequencing, identifying 18 M. abscessus subsp. abscessus erm(41) genotype t28, 10 M. abscessus subsp. abscessus erm(41) genotype c28, 13 M. abscessus subsp. bolletii and 12 M. abscessus subsp. massiliense (Table 2) .
For 48 isolates, a WT band was observed to be concordant with a WT rrl allele. The rrl mutations detected by the GenoType NTM-DR test were in agreement with the PCR sequencing results for three M. abscessus subsp. abscessus erm(41) t28 (a2058c or g mutation) and one M. abscessus subsp. massiliense (a2058g). In addition, the test revealed the mutation a2058g in one isolate of M. abscessus subsp. abscessus erm(41) genotype c28 (MabC6), which was confirmed when the PCR sequencing was repeated.
The rrs mutation a1408g, which was found in two isolates, was detected as a positive MUT1 probe. An additional isolate was detected by a positive MUT1 probe by the test and was confirmed when PCR sequencing was repeated (Mm10). Molecular resistance in non-tuberculous mycobacteria JAC Overall, the rrl genotype determined by the test was 96.2% (51/53) concordant with the clarithromycin susceptibility phenotype: a mutation was detected in four isolates with a high level of non-inducible resistance and no rrl mutations were found in the 47 isolates that showed natural susceptibility to clarithromycin (MIC 4 mg/L after 14 days of incubation) or inducible resistance (increase in MIC after delayed incubation up to .16 mg/L by RAPMYCO testing and 256 mg/L by Etest). We obtained discordant results for two isolates of M. abscessus subsp. bolletii with clarithromycin MIC .256 mg/L after 14 days of incubation, and no rrl mutations were detected by PCR sequencing or NTM-DR testing.
The rrs genotype was concordant with the amikacin antibiotic susceptibility testing for 51/53 (96.2%) isolates. In the two remaining isolates (one M. abscessus subsp. bolletii and one M. abscessus subsp. massiliense) with amikacin MIC .64 mg/L, no mutations were detected in rrs.
Results of GenoType NTM-DR testing for molecular detection of resistance in M. chelonae All 15 M. chelonae isolates were correctly identified and 3 isolates were detected with a mutation in rrl (a2059c in two isolates and a2059g in one). This result was 100% concordant with the PCR sequencing results. Genotypes were 15/15 (100%) concordant with the antibiotic susceptibility testing phenotypes, i.e. the three isolates with rrl mutations were clarithromycin-resistant isolates.
Overall performance of the GenoType NTM-DR test
The results for freshly extracted DNA were similar to those obtained for stored DNA, except for one amplification failure, which was attributed to DNA degradation. Results were reproducible in intra-and inter-laboratory testing. Figure 1 . Prototype of a strip of the GenoType NTM-DR VER 1.0 kit. SP1 to SP7 probes are used for identifying the isolate species, SP9 to erm(41)T28 probes are used for detecting erm(41) genotypes involved in intrinsic resistance to clarithromycin and azithromycin of M. abscessus, rrl probes are used for detecting acquired resistance to clarithromycin and azithromycin, and rrs probes are used for detecting acquired resistance to amikacin and tobramycin. CC, conjugate control; UC, universal control.
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For the four mycobacterial isolates belonging to species other than those targeted (M. tuberculosis, M. scrofulaceum, M. xenopi and M. fortuitum) and the two non-mycobacterial isolates (A. ondotolyticus and N. farcinica), the test was 100% specific as it could not identify them (no specific bands). Weak bands were observed at SP2, SP3 or SP4 for 2/4 mycobacterial isolates and amplification control bands for rrl or rrs appeared weakly positive for 4/6. DNA extracted from two suspensions of M. abscessus (DNA concentrations of 36.1 and 42.2 ng/lL for strains ATCC 19977 and 5-GA-Mab, respectively) yielded positive results for all expected bands down to a low concentration of 0.4 ng/lL. This result is compatible with testing mycobacterial cultures (all our testing was performed on colonies) and possibly smear-positive specimens, although we had tested only one smear-positive (10-100 acidfast bacilli per field) respiratory specimen in which M. chimaera was detected (data not shown).
Overall, the WT and mutated alleles of the rrl and rrs genes were detected by the GenoType NTM-DR test and PCR sequencing with 98% (100/102) agreement ( Table 2 ). The concordance between the test and phenotypic antibiotic susceptibility testing results was 96% (98/102) for clarithromycin and 98% (100/102) for amikacin ( Table 4) . The sensitivity and specificity in the detection of clarithromycin resistance were 79% (15/19) and 100% (83/83) overall, respectively. Given the 20% resistance prevalence observed in our study among the clinical isolates (19/94), the positive and negative predictive values were 100% and 95%, respectively. The sensitivity and specificity in the detection of aminoglycoside resistance were 71% (5/7) and 100% (95/95), respectively. Positive and negative predictive values were 100% and 98%, respectively, for the prevalence of 7.5% observed in our study.
Discussion
Infections due to NTM are increasing, especially in cystic fibrosis patients and in immunosuppressed and aged populations, and recurrences are often observed. [28] [29] [30] [31] [32] Treatment relies on a reduced number of active antibiotics, such as macrolides (mainly clarithromycin and azithromycin) and aminoglycosides (amikacin and tobramycin), and obtaining a successful outcome is related to the susceptibility of the isolates to them. 4, 10, [33] [34] [35] However, acquired resistance is also observed, especially in previously treated patients. 10, 14, 20 Thus, antibiotic susceptibility testing is now recommended before starting therapy and at each recurrent episode.
Antibiotic susceptibility testing is generally performed following the microdilution method according to CLSI recommendations. 7 This method is fastidious and requires teams with expertise. Because the time to results depends on sufficient growth of the mycobacterial species tested, the time to obtaining results is usually as long as 6 weeks for slowly growing mycobacteria such as M. avium complex, with uncertainty arising due to the degradation of antibiotics during this long incubation period. Even in the case of rapidly growing mycobacteria such as M. abscessus, the incubation time should last 14 days to detect inducible clarithromycin resistance related to RNA methylase production. 22 Molecular mechanisms of natural and acquired resistance have been elucidated in the last 20 years and we are now able to diagnose resistance by sequencing a number of genes known to confer resistance, such as rrl and erm(41) for macrolide resistance and rrs for aminoglycoside resistance. 9, 14, 19, 22 Although reference centres can afford this sequencing, a test that is more robust and easy to perform must be available for clinical microbiology laboratories. DNA strip assays are widely used and exhibit good performance. In this study, GenoType NTM-DR results for identification showed 100% concordance with the reference identification done using the results of GenoType CM/AM, hsp65 gene sequencing and ITS (internal transcribed spacer between 16S rRNA and 23S rRNA) for M. avium complex, and erm (41) for M. abscessus. One isolate detected with a mutated rrl allele by GenoType NTM-DR was initially with a WT rrl by sequencing and showed a mix of WT and mutated alleles when retested (see Table 3 and text for detailed results). c One isolate detected with a mutated rrs allele by GenoType NTM-DR was initially with a WT rrs by sequencing and showed a mix of WT and mutated rrs alleles when retested (see Table 3 and text for detailed results).
Molecular resistance in non-tuberculous mycobacteria JAC we applied a new assay to assess resistance in the most frequently observed NTM species responsible for respiratory and extrarespiratory infections.
Our evaluation of the performance of the new NTM-DR assay showed that the assay exhibits high sensitivity for detecting acquired resistance because all isolates with rrl or rrs mutations were detected; moreover, two isolates were diagnosed with heterogeneous resistance, which was missed by initial PCR sequencing. The assay showed high specificity for detecting resistance, meaning that it correctly detects antimicrobial susceptibility. This is important, so drugs to which the organism is susceptible would be used appropriately. Because the prevalence rates of acquired resistance to macrolides and aminoglycosides are similar to those observed in our study, the good performance of the NTM-DR test measured in our study can translate into useful predictive values in clinical practice. 12, 16, 21, 36 We suggest three indications of this test. The first is the detection of acquired resistance, which is mandatory for patients with recurrence or relapse following an initial treatment course. Acquired resistance was mainly observed for infections due to the M. avium complex, M. abscessus and M. chelonae. 9, 14, 15 Second, intrinsic resistance to macrolides was shown to be important for treating M. abscessus infections because isolates not producing efficient RNA methylase, which can be characterized by sequencing erm (41) , especially for the subsp. massiliense, were associated with therapeutic success. [37] [38] [39] [40] [41] [42] The general consensus, highlighted by recent papers, is that determining the erm(41) genotype may now be warranted before treating a case of M. abscessus infection. [43] [44] [45] Third, patients recently diagnosed with a new case of mycobacterial infection but having been treated by antibiotics for other purposes can be tested, such as patients with cystic fibrosis or bronchiectasis who have undergone several courses of azithromycin for non-infectious reasons 46 or of amikacin for Pseudomonas aeruginosa infections. 47 Primary acquired resistance or infection with an M. abscessus subspecies producing RNA methylase to reduce macrolide activity can then be observed. 48 We showed that the limits of the test occurred at the level of nucleotide changes because half of the rrl mutations that hybridized with a specific MUT band varied with sequencing; for instance, a2058g instead of a2058t in one M. avium isolate or the undescribed mutation at position a2057 hybridized with the MUT2 band representing a2058g. This study represents the first description of the mutation a2057c in M. avium, although a mutation at this position (a2057g) was recently described in M. abscessus. Both are associated with a lower level of clarithromycin resistance than those at positions 2058 or 2059. 9, 20, 23 Among various mutations affecting the 16S rRNA (t1406a, a1408g, c1409t and g1491t, E. coli numbering) and conferring resistance, only the mutation a1408g has been observed in clinical isolates. 18, 49 The other limit, which can be an advantage or a disadvantage, is the detection of heteroresistance in five isolates by the test but only three by PCR sequencing. Hetero-resistance can indeed be easier to detect by a reverse hybridization test when several bands are positive (one WT and one or two MUT bands). However, for the mutations not Mougari et al.
present as specific probes (leading to the absence of WT and absence of MUT), this hetero-resistance can be missed, especially if a WT population is also present, as we observed in one isolate. The third limit is that of the molecular detection of resistance with regard to the phenotype determined by antibiotic susceptibility testing. Four isolates resistant to clarithromycin and two resistant to aminoglycosides did not show mutations in the genes we sequenced, either by GenoType NTM-DR or by PCR sequencing. This finding may reflect other mechanisms of resistance or the difficulty of standardizing antibiotic susceptibility testing. 
